US FDA advertising division cites four companies for misleading promotions
This article was originally published in Scrip
Executive Summary
The US FDA has cited four pharmaceutical companies for making false or misleading promotional claims about their drug products in professional journal ads, websites and emails.
You may also be interested in...
Pfizer’s Paxlovid And The Murky World Of Rx Drug Communication
Pfizer social media announcement that it’s seeking full approval for the oral COVID antiviral raise questions about where the line is on promotion versus other communications, FDA’s ability to regulate pharma on social media, and the unique considerations of promotion under EUAs.
Pfizer’s Paxlovid And The Murky World Of Rx Drug Communication
Pfizer social media announcement that it’s seeking full approval for the oral COVID antiviral raise questions about where the line is on promotion versus other communications, FDA’s ability to regulate pharma on social media, and the unique considerations of promotion under EUAs.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.